# A Study to Compare PK and Safety of CKD-381 and D026 in Healthy Male Subjects

> **NCT03444402** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 18 (actual)

## Conditions studied

- GERD

## Interventions

- **DRUG:** CKD-381(formulation I)
- **DRUG:** CKD-381(formulation II)
- **DRUG:** D026(Nexium 40mg)

## Key facts

- **NCT ID:** NCT03444402
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-02
- **Primary completion:** 2018-05-04
- **Final completion:** 2018-05-04
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2018-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03444402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03444402, "A Study to Compare PK and Safety of CKD-381 and D026 in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03444402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*